Pfizer (NYSE:PFE) Trading Down 0.6%

Pfizer Inc. (NYSE:PFE - Get Free Report) shares were down 0.6% on Thursday . The company traded as low as $28.31 and last traded at $28.76. Approximately 10,493,535 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 37,593,551 shares. The stock had previously closed at $28.93.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. StockNews.com raised Pfizer from a "hold" rating to a "buy" rating in a research report on Thursday, August 1st. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. UBS Group lifted their price target on Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a "neutral" rating to an "outperform" rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, September 16th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $34.54.

Pfizer Stock Up 0.1 %

The company's 50 day simple moving average is $29.34 and its 200-day simple moving average is $28.28. The firm has a market cap of $164.13 billion, a P/E ratio of -482.75, a PEG ratio of 1.26 and a beta of 0.68. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts' expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.67 EPS. Research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

Several hedge funds have recently modified their holdings of PFE. Gilbert & Cook Inc. grew its stake in shares of Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 945 shares during the period. Gryphon Financial Partners LLC boosted its holdings in shares of Pfizer by 43.7% in the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company's stock valued at $861,000 after acquiring an additional 8,194 shares in the last quarter. Focus Financial Network Inc. ADV acquired a new stake in Pfizer in the fourth quarter valued at $3,180,000. Catalytic Wealth RIA LLC acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $1,021,000. Finally, Lcnb Corp increased its stake in shares of Pfizer by 2.7% during the 4th quarter. Lcnb Corp now owns 35,780 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 957 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.